Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy

December 21, 2024

Hong Kong DoH Approves AGAMREE® for Duchenne Muscular Dystrophy Treatment.

Santhera Pharmaceuticals announces that the Department of Health of Hong Kong, China, has approved AGAMREE® (vamorolone) for use in patients aged 4 years and older.

- Follow Us -

Tags
AGAMREE
Hong Kong
Santhera
Vamorolone

Disclaimer: No content on this site should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

Researchers Discover 18-Digit Code (Wnt7a) that Allows Proteins to Hitch a Ride Around the Body

UK Approves Givinostat (Duvyzat) for Duchenne Muscular Dystrophy Treatment

Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy

UW Medicine Announces New Gene Therapy Research for Duchenne Muscular Dystrophy

INS1201 Gene Therapy Phase 1 Clinical Trial Begins

Sarepta to Lay Off About 500 Employees After Duchenne Gene Therapy Setbacks

Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Vyondys 53: What Does FDA Rejection Letter Mean?

Hong Kong DoH Approves AGAMREE® for Duchenne Muscular Dystrophy Treatment.

LEAVE A REPLY Cancel reply

Hot Topics

Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy: Treatment & Cost

Related Articles

Accredited Duchenne Centers (ADC) Aims to Provide Uniform and Up-to-date Care for All People Living with Duchenne Muscular Dystrophy

Sarepta Reiterated Total Net Product Revenue of $3.0 Billion in 2025

Agamree (vamorolone) will be Covered in Slovenia by the Slovenian Health Insurance Fund

About us

Latest Articles